Tushar Patel, MB ChB
Although recent advances in direct-acting antiviral therapy have made sustained virologic response (SVR) a reality after hepatitis C infection in patients with cirrhosis, a substantial portion of these individuals will nevertheless develop liver cancer. As such, predicting who will progress is vital to optimizing their care.
“Many patients with chronic hepatitis C virus either have or will undergo treatment with direct-acting antivirals and have sustained virologic